NL-OMON39922已完成不适用
Markers to Determine Arrhythmia Vulnerability in End Stage Heart Failure. - Arrhythmia vulnerability in heart failure, AVES-HF
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients will be included if they are over 18 years and under 80 years and able to give informed consent.
- •Patients with end stage heart failure undergoing LVAD implantation.
排除标准
- •Under 18 and over 80 years
- •The inclusion criteria includes only the study population.
研究者
相似试验
尚未招募
不适用
Identifikation of arrhythmogenic Substrate using echocardiography and MRII48I47Atrial fibrillation and flutterParoxysmal tachycardiaDRKS00017088Charité Campus Charité Mitte120
已完成
不适用
Cardiomyopathy Arrhythmia Risk EvaluationCardiomyopathyNCT02560844University Health Network, Toronto164
已完成
不适用
Arrhythmia Risk Stratification in a Clinical Patient Cohort and Correlation with Genotype and Environmental Modulatorsarrhythmia risk stratification1000752110007510NL-OMON37942Academisch Medisch Centrum100
已完成
不适用
ECG markers for mortality prediction in COVID-19CTRI/2022/04/041892Yenepoya University150
进行中（未招募）
不适用
Discovery of New Biomarkers of Cardiac Susceptibility in adults with Fabry Disease that may be used to develop Targeted Fabry-Specific Therapy DeliveryHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersMetabolic and Endocrine - Metabolic disordersFabry DiseaseACTRN12622000418774The University of Sydney50